Is Your In-House Strategy Ready For The Uncertainties Of Biologic Drug Development?
Author: John Ward, Vice President, Engineering, Patheon
Friday, June 30, 2017
The pharmaceutical industry’s past reliance on blockbuster drugs has evolved to include a focus on developing drugs that treat the unmet needs of smaller patient populations. These niche drugs most often come in the form of biologics, which are an increasingly larger share of new drug approvals in the past decade, from a low of 10 percent to a high of 27 percent. By 2022, 50% of the value of the top 100 products is expected to come from biologics.
Please complete the short form below to download this whitepaper.